Introduction
Validation strategy in biologics is changing as outsourcing, digital tools and new therapy types alter how companies prove process quality. Polaris Market Research reports that the bioprocess validation market size was valued at USD 520.28 million in 2025 and is projected to reach USD 1,129.97 million by 2034, exhibiting a CAGR of 9.0% during 2026–2034, with North America the largest market in 2025. This article examines the segments and technologies growing fastest.
Microbiological Testing Services and Contamination Control
Microbiological testing services are projected to register the fastest CAGR of 9.5% from 2026–2034 among test types. The report attributes this to growing demand for stringent microbial control in biopharmaceutical manufacturing to prevent contamination and ensure sterility. With rising production of biologics and more rigorous regulatory standards, the need for comprehensive testing, including sterility, bioburden and endotoxin testing, has increased significantly. The emphasis on quality in biomanufacturing continues to lift demand for advanced microbiological testing services.
CDMOs and Outsourced Validation
By end user, the market covers pharmaceutical companies, contract development and manufacturing organizations, biotechnology companies and others. Pharmaceutical companies held the largest share of 38.9% in 2025 because of their extensive involvement in production and the need to comply with stringent standards.
CDMOs are expected to grow at the fastest CAGR of 9.6% during 2026–2034. The increasing outsourcing of biopharmaceutical production for cost efficiency and scalability is the key factor. CDMOs offer specialized expertise and infrastructure for validation, serving both large pharmaceutical firms and smaller biotech companies, and rising demand for flexible, efficient manufacturing is fueling their growth. Pharmaceutical companies, for their part, invest heavily to ensure product quality, safety and regulatory compliance, and the growing biologics pipeline drives validation demand in that segment.
Process Analytical Technology and Digital Validation
The adoption of process analytical technology (PAT) frameworks, as encouraged by regulatory agencies, supports better process understanding and control. Combined with automation, real-time monitoring and advanced analytical tools, it enables more efficient and reliable validation. The report names single-use systems, automation and advanced analytical tools as technological advancements significantly affecting the market.
Vendors are responding. In May 2026, Genedata launched Genedata Vico, an AI-native platform for process monitoring, predictive risk assessment and regulatory readiness in biopharmaceutical manufacturing. In April 2026, ValGenesis launched the next-generation VAL, an AI-powered platform for validation automation and lifecycle management. The report's outlook adds that adoption of automation and AI-based validation tools will improve process efficiency, and process analytical technology remains part of that digital shift.
Cell and Gene Therapy Creates New Requirements
Expanding cell and gene therapy pipelines are expected to create new validation requirements and strengthen the market's long-term growth potential. The report's FAQ suggests that a new entrant could offer specialized services for biologics production, particularly in the growing fields of cell and gene therapy, to meet increasing demand for advanced validation in complex biopharmaceuticals. Building partnerships with contract organizations and expanding into developing markets such as Asia Pacific are also noted as ways to gain a competitive edge.
𝐁𝐫𝐨𝐰𝐬𝐞 𝐌𝐨𝐫𝐞 𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬:
https://www.polarismarketresearch.com/industry-analysis/bioprocess-validation-market
Biosimilars and Regional Demand
The growing pipeline of biologics and biosimilars drives demand for validation services among pharmaceutical companies, and the report expects stricter regulatory requirements and rising biosimilars production worldwide to continue supporting demand. In Europe, the growing production of biosimilars further boosts demand. Europe holds a significant share, driven by a strong biopharmaceutical industry, robust regulatory frameworks and substantial investment in biotechnology research, with Germany, the UK and Switzerland key contributors.
Asia Pacific is expected to grow at the fastest CAGR of 9.5% during 2026–2034, with China, India and South Korea emerging as key players thanks to growing manufacturing capabilities, lower production costs and a rising number of contract manufacturing organizations. North America held a 40.0% share in 2025, owing to its established biopharmaceutical industry and stringent regulatory requirements. Within process components, bioreactors are registering the fastest growth, fueled by advances in bioprocessing technologies and the rising adoption of single-use bioreactors.
Key Players and Recent Developments
Key players include Thermo Fisher Scientific Inc., Merck KGaA, Sartorius AG, Danaher Corporation, Charles River Laboratories, SGS SA, Bio-Rad Laboratories, Inc., Lonza Group AG, Eurofins Scientific, Agilent Technologies, Inc., GE HealthCare, Pall Corporation, WuXi AppTec, Toxikon Corporation and Intertek Group plc. The report describes a mix of global conglomerates and specialized providers, with companies focusing on collaborations, acquisitions and expanded global footprints, and investing in advanced technologies and expanded service portfolios.
Recent activity includes ViruSure's March 2026 launch of a GMP-validated viral safety test for faster and broader viral detection in biologics manufacturing, and Thermo Fisher's September 2024 opening of a new bioprocessing facility in North Carolina to enhance production capacity and meet increasing demand for biologics.
Conclusion
The fastest-growing parts of the bioprocess validation market reflect where biopharma is heading: stronger contamination control through microbiological testing services, greater reliance on CDMOs, wider use of process analytical technology, new needs from cell and gene therapy and sustained demand tied to biosimilars. With the market projected to reach USD 1,129.97 million by 2034, B2B decision-makers should align testing, outsourcing and digital investments with these shifts.
More Trending Latest Reports By Polaris Market Research: